| Price | 21.925 on 03-03-2026 at 15:40:08 |
|---|---|
| Change | -0.325 -1.46% |
| Buy | 23.00 |
| Sell | 20.85 |
| Last Trade: | Sell 500.00 at 24.35 |
| Day's Volume: | 0 |
| Last Close: | 22.25 |
| Open: | 21.875 |
| ISIN: | SE0015244520 |
| Day's Range | 20.80 - 21.925 |
| 52wk Range: | 20.80 - 41.40 |
| Market Capitalisation: | - |
| VWAP: | 0.00 |
| Shares in Issue: | 65.80m |
Bioinvent Inter (0H22) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 500 | 24.35 | SI Trade |
12:08:13 - 26-Feb-26 |
| Sell* | 20,000 | 26.25 | SI Trade |
13:46:47 - 25-Feb-26 |
| Sell* | 84 | 26.525 | SI Trade |
10:36:57 - 23-Feb-26 |
| Sell* | 84 | 26.525 | SI Trade |
10:36:57 - 23-Feb-26 |
| Sell* | 99 | 26.65 | SI Trade |
09:52:16 - 23-Feb-26 |
| Sell* | 99 | 26.65 | SI Trade |
09:52:16 - 23-Feb-26 |
| Buy* | 88 | 26.90 | SI Trade |
09:08:59 - 23-Feb-26 |
| Buy* | 88 | 26.90 | SI Trade |
09:08:59 - 23-Feb-26 |
| Buy* | 45 | 25.30 | SI Trade |
10:58:41 - 18-Feb-26 |
| Buy* | 177 | 25.30 | SI Trade |
09:10:13 - 18-Feb-26 |
Bioinvent Inter (0H22) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 26th Feb 2026 7:00 am | MFN | BioInvent International AB: Year-end report January 1 - December 31, 2025 |
| 5th Jan 2026 6:30 am | MFN | BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer |
| 8th Dec 2025 1:00 pm | MFN | BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm | MFN | BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
